Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 85/100

Failure Rate

25.0%

1 terminated/withdrawn out of 4 trials

Success Rate

0.0%

-86.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

2 of 0 completed trials have results

Key Signals

1 recruiting2 with results

Enrollment Performance

Analytics

Phase 1
3(75.0%)
Phase 2
1(25.0%)
4Total
Phase 1(3)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT03957551Phase 1Terminated

Cabozantinib and Pembrolizumab for Advanced Metastatic Melanoma

Role: lead

NCT04599062Phase 1Active Not Recruiting

TVEC and Preop Radiation for Sarcoma (8 ml Dose)

Role: lead

NCT06660810Phase 2Active Not Recruiting

Neoadjuvant Intralesional Injection of Talimogene Laherparepvec

Role: lead

NCT06113809Phase 1Recruiting

Palbociclib and Pembrolizumab in Sarcoma

Role: lead

All 4 trials loaded